TNTommi Nyrönen

Tommi Nyrönen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tommi Nyrönen has a total of 325 co-authors. Here are the top co-authors by number of shared publications:

  • Mark S. Johnson

    Department of Biochemistry and Pharmacy, Åbo Akademi University, FI-20520 Turku, Finland, and Center for Scientific Computing, Espoo, Finland

    7 shared publications
  • Mikael Linden

    CSC - IT Center for Science Ltd, Espoo, Finland

    6 shared publications
  • Aidan Budd

    Structural and Computational Biology (SCB) Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

    4 shared publications
  • Anne Marjamäki

    Department of Biochemistry and Food Chemistry, University of Turku, FI-20014 Turku, Finland, Fatman Bioinformational Designs Ltd., FI-20520 Turku, Finland, Finnish IT Centre for Science, CSC, FI-02101 Espoo, Finland, BioTie Therapies Ltd., FI-20520 Turku, Finland, and Department of Biochemistry and Pharmacy, Åbo Akademi University, FI-20520 Turku, Finland

    4 shared publications
  • Antti Poso

    University of Eastern Finland

    4 shared publications
  • Javier De Las Rivas

    Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC)/University of Salamanca (USAL), and Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Spain

    4 shared publications

Latest Publications

  • Open Access

    Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data

    by Kaisa Litonius, Noora Kulla, Petra Falkenbach, Kati Kristiansson, E. Katriina Tarkiainen, Liisa Ukkola‐Vuoti, Kristiina Cajanus, Mari Korhonen, Sofia Khan, Johanna Sistonen, et al.

    Implementation of pharmacogenetic testing in clinical care has been slow and with few exceptions is hindered by the lack of real‐world evidence on how to best target testing. In this retrospective register‐based study, we analyzed a nationwide cohort of 1,425,000 patients discharged from internal medicine or surgical wards and a cohort of 2,178 university hospital patients for purchases and prescriptions of pharmacogenetically actionable drugs. Pharmacogenetic variants were obtained from whole genome genotype data for a subset (n = 930) of the university hospital patients. We investigated factors associated with receiving pharmacogenetically actionable drugs and developed a literature‐based cost–benefit model for pre‐emptive pharmacogenetic panel testing. In a 2‐year follow‐up, 60.4% of the patients in the nationwide cohort purchased at least one pharmacogenetically actionable drug, most commonly ibuprofen (25.0%) and codeine (19.4%). Of the genotyped subset, 98.8% carried at least one actionable pharmacogenetic genotype and 23.3% had at least one actionable gene‐drug pair. Patients suffering from musculoskeletal or cardiovascular diseases were more prone to receive pharmacogenetically actionable drugs during inpatient episode. The cost–benefit model included frequently dispensed drugs in the university hospital cohort, comprising ondansetron (19.4%), simvastatin (7.4%), clopidogrel (5.0%), warfarin (5.1%), (es)citalopram (5.3%), and azathioprine (0.5%). For untargeted pre‐emptive pharmacogenetic testing of all university hospital patients, the model indicated saving €17.49 in direct healthcare system costs per patient in 2 years without accounting for the cost of the test itself. Therefore, it might be reasonable to target pre‐emptive pharmacogenetic testing to patient groups most likely to receive pharmacogenetically actionable drugs.


  • Open Access

    International federation of genomic medicine databases using GA4GH standards

    by Adrian Thorogood, Heidi L. Rehm, Peter Goodhand, Angela J.H. Page, Yann Joly, Michael Baudis, Jordi Rambla, Arcadi Navarro, Tommi H. Nyronen, Mikael Linden, et al.


  • Open Access

    GA4GH Passport standard for digital identity and access permissions

    by Craig Voisin, Mikael Linden, Stephanie O.M. Dyke, Sarion R. Bowers, Pinar Alper, Maxmillian P. Barkley, David Bernick, Jianpeng Chao, Mélanie Courtot, Francis Jeanson, et al.


  • Top Cited Papers
    Open Access

    The Data Use Ontology to streamline responsible access to human biomedical datasets

    by Jonathan Lawson, Moran N. Cabili, Giselle Kerry, Tiffany Boughtwood, Adrian Thorogood, Pinar Alper, Sarion R. Bowers, Rebecca R. Boyles, Anthony J. Brookes, Matthew Brush, et al.


  • Open Access

    Empirical validation of an automated approach to data use oversight

    by Moran N. Cabili, Jonathan Lawson, Andrea Saltzman, Greg Rushton, Pearl O’rOurke, John Wilbanks, Laura Lyman Rodriguez, Tommi Nyronen, Mélanie Courtot, Stacey Donnelly, et al.


  • Open Access

    Common ELIXIR Service for Researcher Authentication and Authorisation

    by Mikael Linden, Michal Prochazka, Ilkka Lappalainen, Dominik Bucik, Pavel Vyskocil, Martin Kuba, Sami Silén, Peter Belmann, Alexander Sczyrba, Steven Newhouse, et al.

    A common Authentication and Authorisation Infrastructure (AAI) that would allow single sign-on to services has been identified as a key enabler for European bioinformatics. ELIXIR AAI is an ELIXIR service portfolio for authenticating researchers to ELIXIR services and assisting these services on user privileges during research usage. It relieves the scientific service providers from managing the user identities and authorisation themselves, enables the researcher to have a single set of credentials to all ELIXIR services and supports meeting the requirements imposed by the data protection laws. ELIXIR AAI was launched in late 2016 and is part of the ELIXIR Compute platform portfolio. By the end of 2017 the number of users reached 1000, while the number of relying scientific services was 36. This paper presents the requirements and design of the ELIXIR AAI and the policies related to its use, and how it can be used for serving some example services, such as document management, social media, data discovery, human data access, cloud compute and training services.


  • Open Access

    Registered access: authorizing data access

    by Stephanie O. M. Dyke, Mikael Linden, Ilkka Lappalainen, Jordi Rambla De Argila, Knox Carey, David Lloyd, J. Dylan Spalding, Moran N. Cabili, Giselle Kerry, Julia Foreman, et al.

    The Global Alliance for Genomics and Health (GA4GH) proposes a data access policy model—“registered access”—to increase and improve access to data requiring an agreement to basic terms and conditions, such as the use of DNA sequence and health data in research. A registered access policy would enable a range of categories of users to gain access, starting with researchers and clinical care professionals. It would also facilitate general use and reuse of data but within the bounds of consent restrictions and other ethical obligations. In piloting registered access with the Scientific Demonstration data sharing projects of GA4GH, we provide additional ethics, policy and technical guidance to facilitate the implementation of this access model in an international setting.


  • Open Access

    ELIXIR Finland Services

    by Tommi Nyrönen

    ELIXIR Finland is the national node in the European Life Science Infrastructure for Biological Information hosted at the CSC -­‐ IT Center Science Ltd. Node specialises in virtualised compute and storage and data access infrastructure for biological biomedical organisations and is linked with European high‐performance network to ELIXIR datacentres.

  • Open Access

    Orchestrating differential data access for translational research: a pilot implementation

    by Marco Brandizi, Olga Melnichuk, Raffael Bild, Florian Kohlmayer, Benedicto Rodriguez-Castro, Helmut Spengler, Klaus A. Kuhn, Wolfgang Kuchinke, Christian Ohmann, Timo Mustonen, et al.

    Translational researchers need robust IT solutions to access a range of data types, varying from public data sets to pseudonymised patient information with restricted access, provided on a case by case basis. The reason for this complication is that managing access policies to sensitive human data must consider issues of data confidentiality, identifiability, extent of consent, and data usage agreements. All these ethical, social and legal aspects must be incorporated into a differential management of restricted access to sensitive data. In this paper we present a pilot system that uses several common open source software components in a novel combination to coordinate access to heterogeneous biomedical data repositories containing open data (open access) as well as sensitive data (restricted access) in the domain of biobanking and biosample research. Our approach is based on a digital identity federation and software to manage resource access entitlements. Open source software components were assembled and configured in such a way that they allow for different ways of restricted access according to the protection needs of the data. We have tested the resulting pilot infrastructure and assessed its performance, feasibility and reproducibility. Common open source software components are sufficient to allow for the creation of a secure system for differential access to sensitive data. The implementation of this system is exemplary for researchers facing similar requirements for restricted access data. Here we report experience and lessons learnt of our pilot implementation, which may be useful for similar use cases. Furthermore, we discuss possible extensions for more complex scenarios.


  • Open Access

    Future opportunities and trends for e-infrastructures and life sciences: going beyond the grid to enable life science data analysis

    by Afonso M. S. Duarte, Fotis E. Psomopoulos, Christophe Blanchet, Alexandre M. J. J. Bonvin, Manuel Corpas, Alain Franc, Rafael C. Jimenez, Jesus M. de Lucas, Tommi Nyrönen, Gergely Sipos, et al.

    With the increasingly rapid growth of data in Life Sciences we are witnessing a major transition in the way research is conducted, from hypothesis-driven studies to data-driven simulations of whole systems. In the context of the European Grid Infrastructure Community Forum 2014 (Helsinki, 19–23 May 2014), a workshop was held aimed at understanding the state of the art of Grid/Cloud computing in EU research as viewed from within the field of Life Sciences. The workshop brought together Life Science researchers and infrastructure providers from around Europe and facilitated networking between them within the context of EGI. The first part of the workshop included talks from key infrastructures and projects within the Life Sciences community. This was complemented by technical talks that established the key aspects present in major research approaches. Finally, the discussion phase provided significant insights into the road ahead with proposals for possible collaborations and suggestions for future actions.